Lindbrook Capital’s Revolution Medicines RVMD Stock Holding History

Lindbrook Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$9.37K	Sell	265 -55	-17%	-$2.23K	﹤0.01%	1683
2024 Q4	$14K	Buy	320 +21	+7%	+$1.06K	﹤0.01%	1470
2024 Q3	$13.6K	Sell	299 -31	-9%	-$1.35K	﹤0.01%	1514
2024 Q2	$12.8K	Buy	330 +178	+117%	+$6.65K	﹤0.01%	1490
2024 Q1	$4.9K	Buy	152 +55	+57%	+$1.63K	﹤0.01%	1900
2023 Q4	$2.78K	Buy	97 +46	+90%	+$1.1K	﹤0.01%	2154
2023 Q3	$1.41K	Buy	51 +41	+410%	+$1.22K	﹤0.01%	2246
2023 Q2	$268	Hold	10	–	–	﹤0.01%	2635
2023 Q1	$217	Sell	10 -63	-86%	-$1.55K	﹤0.01%	2720
2022 Q4	$1.74K	Buy	73 +60	+462%	+$1.28K	﹤0.01%	2287
2022 Q3	$0	Hold	13	–	–	﹤0.01%	2872
2022 Q2	$0	Buy	+13	New	+$253	﹤0.01%	2728

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's RVMD Position: Q1 2025 in Review

Lindbrook Capital reduced its Revolution Medicines (RVMD) stake by 17% in Q1 2025, selling an estimated $2.23K and leaving 265 shares worth $9.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1683.

Lindbrook Capital first reported a position in RVMD in Q2 2022 and has held it in 12 quarters since. The position peaked at $14K in Q4 2024. 284 funds tracked by Wall St. Rank hold RVMD as of Q1 2025.

Lindbrook Capital held 265 shares of Revolution Medicines worth $9.37K as of Q1 2025.
Lindbrook Capital sold 55 Revolution Medicines shares in Q1 2025, an estimated $2.23K.
Revolution Medicines made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1683 holding.
Lindbrook Capital first reported a position in Revolution Medicines in Q2 2022 and has held it in 12 quarters since.
Lindbrook Capital's Revolution Medicines position peaked at $14K in Q4 2024.
284 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.